Moderna Inc. /zigman2/quotes/205619834/composite MRNA +1.07% said Monday the U.K. regulator has authorized its bivalent COVID vaccine booster for use in adults aged 18 and older. The Medicines and Healthcare products Regulatory Agency gave the nod to the booster dubbed mRNA-1273.214 which targets the original virus strain, as well as the omicron variant. The decision was based on data from a Phase 2/3 trial that met all primary goals, including superior neutralizing antibody response against omicron (BA.1) when compared to a 50 ug booster dose of mRNA-1273. "A booster dose of mRNA-1273.214 increased neutralizing geometric mean titers (GMT) against omicron approximately 8-fold above baseline levels," the company said in a statement. The booster further "elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to the currently authorized booster (mRNA-1273) regardless of prior infection status or age," it added. Moderna shares were slightly lower premarket, and have fallen 33% in the year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +2.06% has fallen 10%.